美沙拉秦缓释颗粒剂联合五味苦参肠溶胶囊治疗溃疡性结肠炎的疗效观察  

Observation of efficacy of mesalazine sustained-release granules combined with composite sophora colon-soluble capsules in the treatment of ulcerative colitis

作　　者：刁凌云[1] 王胜英 皇金萍[1] 罗玉国 葛飞 孙茂秋 DIAO Lingyun;WANG Shengying;HUANG Jinping;LUO Yuguo;GE Fei;SUN Maoqiu(Department of Gastroenterology of Xuzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine,Xuzhou,221000,China;Nursing Department of Haian Hospital of Traditional Chinese Medicine Affiliated to Medical College of Yangzhou University)

机构地区：[1]南京中医药大学附属徐州市中医院消化科,江苏徐州221000 [2]扬州大学医学院附属海安市中医院护理部

出　　处：《包头医学院学报》2021年第10期43-48,共6页Journal of Baotou Medical College

基　　金：江苏省自然科学基金面上项目(BK20181235)。

摘　　要：目的:观察美沙拉秦缓释颗粒剂联合五味苦参肠溶胶囊治疗湿热内蕴型溃疡性结肠炎(ulcerative colitis,UC)的临床疗效及对T淋巴细胞亚群及血清炎症因子的影响。方法:收集2018年06月至2020年06月在我院脾胃科门诊治疗的UC患者120例为研究对象,随机分为A组(40例,口服美沙拉秦缓释颗粒剂),B组(40例,口服五味苦参肠溶胶囊),C组(40例,联合口服美沙拉秦缓释颗粒剂及五味苦参肠溶胶囊,服药剂量及方法同前)。3个组疗程均为4周,分别于治疗前后采用改良Mayo评分评估临床疗效,检测3个组患者治疗前后T淋巴细胞亚群(CD4+、CD8+)、血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)水平及不良反应发生情况。结果:C组临床疗效总有效率为95.0%(38/40),高于A组的75.0%(30/40)和B组的70.0%(28/40)(P<0.05);A、B、C各组患者治疗后Mayo评分减低(P<0.05),C组低于A组和B组(P<0.05);A、B、C各组患者治疗后CD4+高于治疗前(P<0.05),CD8+低于治疗前(P<0.05),C组治疗后CD4+水平高于A组和B组(P<0.05),CD8+水平低于A组和B组(P<0.05);A、B、C各组患者治疗后血清TNF-α、IL-6、IL-8均低于治疗前(P<0.05),C组低于A组和B组(P<0.05);3个组不良反应发生率比较差异无统计学意义(P>0.05)。结论:美沙拉秦缓释颗粒剂联合五味苦参肠溶胶囊可以改善湿热内蕴型UC患者的临床疗效,其机制可能与提升UC患者免疫功能、有下调炎性因子表达有关。Objective:To observe the clinical efficacy of mesalazine sustained-release granules combined with composite sophora colon-soluble capsules in the treatment of damp-heat ulcerative colitis(UC)and its effect on T lymphocyte subsets and serum inflammatory factors.Methods:A total of 120 patients with UC were collected and randomly divided into Group A(40 cases,taking mesalazine sustained-release granules orally),Group B(40 cases,taking composite sophora colon-soluble capsules orally),and Group C(40 cases,taking mesalamine sustained-release granules and composite sophora colon-soluble capsules orally,with the same dosage and method as above).Three groups were all treated for 4 weeks.The modified Mayo score was used to evaluate the clinical efficacy before and after treatment.The three groups of patients were detected for T lymphocyte subset(CD4+,CD8+),serum tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),and interleukin-8(IL-8)levels and adverse reactions before and after treatment.Results:The total effective rate of clinical efficacy in Group C was 95.0%(38/40),which was higher than that 75.0%in Group A(30/40)and 70.0%in Group B(28/40)(P<0.05);the Mayo scores of patients in Group A,Group B and Group C decreased after treatment,and those in Group C were lower than in Group A and Group B(P<0.05);CD4+of patients in Group A,Group B,and Group C after treatment was higher than before treatment,CD8+was lower than before treatment,CD4+level of Group C after treatment was higher than that of Group A and Group B,and CD8+level was lower than that of Group A and Group B(P<0.05);serum TNF-α,IL-6 and IL-8 of patients in Group A,Group B and Group C after treatment was lower than before treatment,and that in Group C was lower than Group A and Group B(P<0.05);the incidence of adverse reaction in Group C was 20.00%(8/40),there was no significant difference compared to 15.00%(6/40)in Group A and 17.50%(7/40)in Group B(P>0.05).Conclusion:Mesalazine sustained-release granules combined with Composite sophora colon-soluble capsules c

关 键 词：美沙拉秦缓释颗粒剂 五味苦参肠溶胶囊 溃疡性结肠炎 免疫功能 血清炎症因子 

分 类 号：R28[医药卫生—中药学]